CT52923
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer[1].
Product Specifications
CAS Number
205256-55-9
UNSPSC
12352005
Target
PDGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ct52923.html
Concentration
10mM
Purity
98.58
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
S=C(N1CCN(CC1)C2=C3C=C(OC)C(OC)=CC3=NC=N2)NCC4=CC=C5OCOC5=C4
Molecular Formula
C23H25N5O4S
Molecular Weight
467.54
References & Citations
[1]J C Yu, et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther. 2001 Sep;298 (3) :1172-8.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
